BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter study

Background: Therapeutic options for BRAFV600-mutant melanoma in patients who progress on BRAF/MEK-inhibitors (BRAF/MEKi) and immune-checkpoint-inhibitor (ICI) therapy, are limited. We conducted a retrospective registry study to investigate post-ICI rechallenge with BRAF/MEKi, stratified by type of i...

Полное описание

Библиографические подробности

Главные авторы:	Michael Weichenthal, Iva Gavrilova, Peter Mohr, Berna C. Özdemir, Nethanel Asher, Eva Ellebaek, Jens Ulrich, Alexander Kreuter, Aleksander Popovic, Christina Ruhlmann, Igor Stojkovski, Shaked Lev-Ari, Edgar Dippel, Almudena García Castaño, Lorena Bellido Hernández, Henrik Schmidt, Egle Ramelyte, Dimitrios Ziogas, Luisa Piccin, Katarzyna Kozak, Dirk Debus, Gergana Shalamanova-Deleva, Ronnie Shapira, John Haanen, Inge Marie Svane, Paolo A. Ascierto, Piotr Rutkowski, Helen Gogas, Joanna Mangana, Lars Bastholt, Dirk Schadendorf
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-01-01
Серии:	EJC Skin Cancer
Предметы:	Melanoma BRAF inhibitor MEK inhibitor Real-world-data Rechallenge
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2772611826000030
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!